Technological Innovations in Drug-Eluting and Bioresorbable Stents to Drive Coronary Stents Market to USD 26,060.6 Mn by 2033 at 8.1% CAGR – Coherent Market Insights
The Coronary Stents Market, estimated at USD 15,078.6 Mn in 2026, is expected to exhibit a CAGR of 8.1% and reach USD 26,060.6 Mn by 2033.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
The key players in the market are focusing on adoption of organic growth strategies such as product launch in order to strengthen their market presence in the global coronary stents market, is expected to drive the market growth over the forecast period. For instance, in April 2025, Eurocor Tech GmbH, a designer and manufacturer of cardiovascular and endovascular products, announced the launch of its new product, Eurolimus. The product features and open-cell design with interlinks, allows for high flexibility and overexpansion capabilities while offering one of the lowest strut thicknesses in the market.
Global Coronary Stents Market: Key Developments
- In March 2026, Philips launched IntraSight Plus, an integrated interventional cardiology platform designed to simplify complex coronary procedures. FDA 510(k)-cleared in the U.S. and CE-marked in Europe, the system combines intravascular ultrasound, iFR/FFR physiology, co-registration, treatment planning, and real-time device visualization on one screen. Philips states that the platform can reduce system operation time by up to 47%, while improving workflow efficiency, bedside control, stent placement, precision, and clinical decision-making. (Source: Philips)
- In June 2026, Terumo Interventional Systems completed the first U.S. procedure using its OPUSWAVE Dual Sensor Imaging System. The platform integrates intravascular ultrasound and optical frequency domain imaging through one DualView catheter, providing simultaneous deep-vessel and high-resolution surface visualization. Physicians can assess plaque composition, lesion morphology, stent sizing, placement, and deployment within one workflow. The innovation supports more informed decisions and improved precision during complex coronary interventions and stent optimization. (Source: Terumo Interventional Systems)
- In April 2026, Conavi Medical received U.S. FDA 510(k) clearance for its next-generation hybrid IVUS-OCT intravascular imaging system. The technology co-registers and co-aligns intravascular ultrasound and optical coherence tomography beams, enabling simultaneous assessment of coronary anatomy within a single workflow. The system is designed to improve lesion evaluation, guide coronary stent sizing and placement, and verify deployment. Conavi expects to begin its commercial launch during the second half of 2026. (Source: Conavi Medical)
- In April 2025, Translumina, a global developer and manufacturer of innovative cardiovascular medical devices used in interventional cardiology, announced the launch of VIVO ISAR, its latest generation dual drug polymer-free coated stent (DDCS), in various international markets, including Europe.
- In February 2025, Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced its partnership with Innova Vascular, Inc., a medical device company to develop a full line of novel thrombectomy devices.
- In June 2025, Sahajanand Medical Technologies Pvt. Ltd, a leading developer and manufacturer of minimally invasive coronary stent systems, announced that it has received full reimbursement for Supraflex and Supraflex Cruz coronary stent from the Ministry of Health and Public Affairs of France.
- In November 2025, Purple MicroPort, an Indian joint venture company of MicroPort Scientific Corporation, launched the Firehawk IN Rapamycin Target Eluting Coronary Stent System for the Indian drug eluting stent (DES) market.